TY  - JOUR
AU  - Romaniello, Donatella
AU  - Marrocco, Ilaria
AU  - Belugali Nataraj, Nishanth
AU  - Ferrer, Irene
AU  - Drago-Garcia, Diana
AU  - Vaknin, Itay
AU  - Oren, Roni
AU  - Lindzen, Moshit
AU  - Ghosh, Soma
AU  - Kreitman, Matthew
AU  - Kittel, Jeanette Clarissa
AU  - Gaborit, Nadege
AU  - Bergado Baez, Gretchen
AU  - Sanchez, Belinda
AU  - Eilam, Raya
AU  - Pikarsky, Eli
AU  - Yarden, Yosef
AU  - Paz Ares, Luis Gonzaga
PY  - 2020
DO  - 10.3390/cancers12092394
SN  - 2072-6694
UR  - http://hdl.handle.net/20.500.12105/10990
AB  - Although two growth factor receptors, EGFR and HER2, are amongst the best targets for cancer treatment, no agents targeting HER3, their kinase-defective family member, have so far been approved. Because emergence of resistance of lung tumors to EGFR...
LA  - eng
PB  - Multidisciplinary Digital Publishing Institute (MDPI)
TI  - Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor.
TY  - journal article
ER  -